Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan

Clinical Cancer Research

Volumn 8, Issue 8, 2002, Pages 2605-2611

  Xu, Guang ^a   Zhang, Wanghai ^a   Ma, Margaret K ^a   McLeod, Howard L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYLESTERASE; IRINOTECAN; CAMPTOTHECIN; DRUG DERIVATIVE; ISOPROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG RESPONSE; GALLBLADDER TUMOR; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER; LYMPHOMA; PRIORITY JOURNAL; SOLID TUMOR; WESTERN BLOTTING; BIOSYNTHESIS; CELL CULTURE; CYTOSOL; DOSE RESPONSE; KINETICS; LIVER MICROSOME; METABOLISM; NEOPLASM; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS;

BLOTTING, WESTERN; CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMAN; IMMUNOHISTOCHEMISTRY; KINETICS; LIVER; MICROSOMES, LIVER; NEOPLASMS; PROTEIN ISOFORMS; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED; CARBOXYLESTERASE; HUMANS;

EID: 0036023423     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Irinotecan in the treatment of colorectal cancer: Clinical overview
2. Irinotecan in the first-line treatment of colorectal cancer
3. Irinotecan: A new agent comes of age
4. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38
5. Characterization of irinotecan hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
6. Metabolic activation of CPT-11,7-ethyl-10-[4-(1-piperidino)- 1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase
7. Comparison of activation of irinotecan by rabbit and human carboxylesterase for use in enzyme/prodrug therapy
8. In situ subcellular localization of epitope-tagged human and rabbit carboxylesterase
9. Irinotecan converting carboxylesterase and topoisomerase activities in tumor and normal colon and liver tissues
10. Proficient metabolism of iriotecan by a human intestinal carboxylesterase
11. Dexamethasone differentially regulates expression of carboxylesterase genes in human and rats
12. Immunohistochemistry with an antibody to human liver carboxylesterase in human brain tissues
13. The mammalian carboxylesterases: From molecules to functions
14. Human liver cocaine esterases: Ethanol-mediated formation of ethylcocaine
15. Cloning and expression of cDNA encoding carboxylesterase isozymes from mammals and humans
16. Carboxylerases with different substrate specificity in human brain extracts
17. Human carboxylesterases in term placentae: Enzymatic characterization, molecular cloning and evidence for the existence of multiple forms
18. Identification and activation of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug
19. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase
20. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials
21. Phase I pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
22. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients
23. Phase I pharmacokinetic trial of weekly CPT-11
24. Strategies for enzyme/prodrug cancer therapy
25. Comprehensive evaluation of carboxylesterase-2 expression in normal tissue using tissue array analysis
26. Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic β-cells
27. Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance
28. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions
29. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11)
30. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase
31. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), by human liver carboxylesterase
32. Irinotecan in cancers of the lung and cervix
33. Irinotecan (CPT-11) in patients (Pts) with advanced gallbladder (GB) carcinoma (CA): A North Central Cancer Treatment Group (NCCTG) Phase II study
34. Clinical activity spectrum of irinotecan
35. Topoisomerase I inhibitors in the treatment of colorectal cancer
36. Direct translation of a protracted irinotecan schedule from a xenograft model to a Phase I trial in children
37. Preclinical and clinical trials of topoisomerase inhibitors
38. Comparative localization of carboxylesterase in F344 rat, beagle dog, and human nasal tissue
39. Correlation of carcinoembryonic antigen content with carboxylesterase activity in benign and malignant human tissues
40. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: Comparison with p-nitro-phenylacetate converting carboxylesterase activity
41. Interindividual variation in carboxylesterase levels in human liver microsomes
42. Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: Correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan
43. Determinants of CPT-11 and SN-38 activities in human lung cancer cells
44. CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants